Project description:To systematically characterize anti-PD-1/PD-L1 immunotherapy-related changes in serum glycoproteins and discover novel biomarkers related to treatment response, we analyzed a series of sera samples from patients with metastatic lung squamous cell carcinoma (SCC) and lung adenocarcinoma (ADC), collected before and during ICIs treatment, with mass-spectrometry-based label-free quantification methodology.

2022-12-31 | PXD039141 |

Knockout of immunotherapy prognostic marker genes eliminates the effect of the anti-PD-1 treatment

Project description:We present a pan-cancer integrated analysis of transcriptome, exome and clinical records of patients. Herein, we identified candidate genes as potential biomarkers to predict clinical outcome of immunotherapy. We further explored the function of two IPM genes in vivo. Knockout of MALT1, which is critical for the T cell receptor signaling, can eliminate the anti-tumor effect of anti-PD-1 treatment completely by impairing the activation of CD8+ T cells. Notably, knockout of CLEC4D, a C-type lectin receptor that expressed on myeloid cells, also reduced the effect of anti-PD-1 treatment potentially through maintaining the immunosuppressive effects of myeloid cells.

2020-12-01 | GSE158056 | GEO

Intratumoral TFR cells curtail anti-PD-1 treatment efficacy [human]

Project description:Intratumoral TFR cells curtail anti-PD-1 treatment efficacy [human]

| PRJNA547554 | ENA

Intratumoral TFR cells curtail anti-PD-1 treatment efficacy [mouse]

Project description:Intratumoral TFR cells curtail anti-PD-1 treatment efficacy [mouse]

| PRJNA547567 | ENA

Transcriptome of YTN16 tumor tissues after treatment with anti-PD-L1 or anti-CTLA-4

Project description:A murine gastric cancer YTN16 is sensitive to anti-CTLA-4, but resistant to anti-PD-L1. To investigate tumor microenvironments after treatment of these mAbs, we performed RNA-Seq analyses.

2022-01-19 | GSE184092 | GEO

Humoral determinants of checkpoint immunotherapy: anti-TL1A treatment has a synergistic effect with anti-PD-1 treatment

Project description:Humoral determinants of checkpoint immunotherapy: anti-TL1A treatment has a synergistic effect with anti-PD-1 treatment

| PRJNA1250282 | ENA

single cell-RNA sequencing for Immune cells from mouse brain tumor post anti PD-1 treatment

Project description:To evaluate the influence of ablating Fcgr2b on anti-PD-1 treatment efficacy, we administered GL261 cells to both Fcgr2b knockout and wild-type (WT) mice, followed by treatment with anti-PD-1. Afterwards, we isolated immune cells from the brains of these mice for further analysis.

2024-11-06 | GSE262592 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data